title: Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer.
abstract: We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient's specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.
authors.affiliation: Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang, 110004, China.
authors.forename: Xin-yan
authors.initials: XY
authors.lastname: Wang
authors.forename: Hai-jiao
authors.initials: HJ
authors.lastname: Wang
authors.forename: Xiu-qin
authors.initials: XQ
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D002945:Cisplatin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D061105:Peroxiredoxin III / Q000096:biosynthesis / Q000378:metabolism*
chemical_list: D061105:Peroxiredoxin III; D002945:Cisplatin
references.citation: Front Oncol. 2012 Apr 10;2:33
references.pmid: 22655269
references.citation: Environ Health Perspect. 1998 Feb;106 Suppl 1:289-95
references.pmid: 9539021
references.citation: J Biol Chem. 2004 Oct 1;279(40):41975-84
references.pmid: 15280382
references.citation: Int J Mol Sci. 2011;12(10):7163-85
references.pmid: 22072940
references.citation: Anticancer Res. 2001 May-Jun;21(3B):2085-90
references.pmid: 11497302
references.citation: Cancer Res. 1999 Jul 1;59(13):3077-83
references.pmid: 10397248
references.citation: Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7017-21
references.pmid: 8041738
references.citation: Proc Natl Acad Sci U S A. 2002 May 14;99(10):6649-54
references.pmid: 12011429
references.citation: Int J Oncol. 2010 Feb;36(2):359-64
references.pmid: 20043069
references.citation: Expert Rev Proteomics. 2008 Aug;5(4):551-60
references.pmid: 18761466
references.citation: Cancer Invest. 2011 Jan;29(1):21-8
references.pmid: 21166495
references.citation: FEBS Lett. 2010 Jul 16;584(14):3185-92
references.pmid: 20541551
references.citation: Oncogene. 2003 Oct 20;22(47):7265-79
references.pmid: 14576837
references.citation: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references.pmid: 21685461
references.citation: Nat Rev Cancer. 2003 Jul;3(7):502-16
references.pmid: 12835670
references.citation: Int J Cancer. 2004 Sep 10;111(4):514-21
references.pmid: 15239128
references.citation: J Urol. 2006 Apr;175(4):1512-6
references.pmid: 16516038
references.citation: Int J Cancer. 2009 Jul 15;125(2):264-75
references.pmid: 19408305
references.citation: J Radiat Res. 2005 Sep;46(3):305-12
references.pmid: 16210786
references.citation: Biol Chem. 2002 Mar-Apr;383(3-4):347-64
references.pmid: 12033427
references.citation: Mol Cancer Ther. 2009 May;8(5):1292-304
references.pmid: 19383853
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3418-24
references.pmid: 12960131
references.citation: Trends Biochem Sci. 2003 Jan;28(1):32-40
references.pmid: 12517450
references.citation: Mol Cancer Res. 2003 Jul;1(9):682-9
references.pmid: 12861054
references.citation: Gynecol Oncol. 2006 Aug;102(2):348-55
references.pmid: 16545436
references.citation: Biochem Biophys Res Commun. 1994 Sep 15;203(2):1175-80
references.pmid: 8093036
references.citation: Oncol Rep. 2009 Jun;21(6):1391-6
references.pmid: 19424615
references.citation: J Exp Clin Cancer Res. 2009 Jun 30;28:93
references.pmid: 19566940
references.citation: Respirology. 2006 May;11(3):269-75
references.pmid: 16635084
references.citation: Anticancer Res. 2001 Mar-Apr;21(2A):1129-33
references.pmid: 11396151
references.citation: Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4
references.pmid: 1348364
references.citation: Int J Pharm. 2010 Apr 15;389(1-2):10-7
references.pmid: 20060458
references.citation: J Pathol. 2002 Mar;196(3):316-23
references.pmid: 11857495
references.citation: BMC Cancer. 2010 Mar 22;10:104
references.pmid: 20307276
references.citation: Anticancer Res. 2002 Nov-Dec;22(6A):3331-5
references.pmid: 12530083
references.citation: Biologics. 2012;6:147-54
references.pmid: 22807625
references.citation: Cancer Lett. 2009 Mar 8;275(1):109-16
references.pmid: 19056166